Neural representations of absolute and relative magnitudes in symbolic and nonsymbolic formats.

Humans differ from other animal species in their unique ability to use symbols to represent numerical information. This ability is thought to emerge from the "neural recycling" of mechanisms supporting nonsymbolic magnitudes in the intraparietal sulcus (IPS), a hypothesis that has been applied to both absolute magnitudes (e.g.

The ratio processing system and its role in fraction understanding: Evidence from a match-to-sample task in children and adults with and without dyscalculia.

It has been hypothesised that the human neurocognitive architecture may include a perceptual ratio processing system (RPS) that supports symbolic fraction understanding. In the present study, we aimed to provide further evidence for the existence of the RPS by exploring whether individuals with a range of math skills are indeed perceptually sensitive to non-symbolic ratio magnitudes. We also aimed to test to what extent the RPS may underlie symbolic fraction processing in those individuals.

Azadirachtin inhibits amyloid formation, disaggregates pre-formed fibrils and protects pancreatic β-cells from human islet amyloid polypeptide/amylin-induced cytotoxicity.

The human islet amyloid polypeptide (hIAPP) or amylin is the major constituent of amyloidogenic aggregates found in pancreatic islets of type 2 diabetic patients that have been associated with β-cell dysfunction and/or death associated with type 2 diabetes mellitus (T2DM). Therefore, developing and/or identifying inhibitors of hIAPP aggregation pathway and/or compound that can mediate disaggregation of preformed aggregates holds promise as a medical intervention for T2DM management. In the current study, the anti-amyloidogenic potential of Azadirachtin (AZD)-a secondary metabolite isolated from traditional medicinal plant Neem ()-was investigated by using a combination of biophysical and cellular assays.

miRNAs: early prognostic biomarkers for Type 2 diabetes mellitus?

Type 2 diabetes mellitus (T2DM) has reached epidemic proportions and is associated with peripheral insulin resistance. The currently used therapies aim to delay progression of T2DM. Their efficacy could drastically be improved if implemented at earlier stages.